Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05968690 · ClinicalTrials.gov registry record · Phase 1
Naltrexone and Propranolol Combined With Immunotherapy
A Phase 1 study of Advanced Melanoma, sponsored by Sarah Weiss.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05968690 is a Phase 1 study of Advanced Melanoma that is actively recruiting participants, run by Sarah Weiss. The registered enrollment target is 12 participants, below the 171-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05968690, a Phase 1 study of Advanced Melanoma, is actively recruiting participants, sponsored by Sarah Weiss.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Various forms of stress can promote cancer development and growth and negatively impact the immune system's response to tumors. Beta-adrenergic and opioid receptors co-exist in many cells including immune cells and are integral components of the body's response to stress. Pre-clinical studies have demonstrated that dual blockade of these receptors can decrease tumor growth and modulate the anti-tumor immune response. This clinical trial investigates the safety and potential therapeutic benefits of combining a beta-adrenergic blocker (propranolol) and an opioid receptor antagonist (naltrexone) with immune checkpoint inhibitors in patients with advanced melanoma.
Conditions Studied
Interventions
- DRUG Propranolol
- DRUG Naltrexone
Study Locations (1)
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05968690
The ClinicalTrials.gov registry entry for NCT05968690 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (93% lower). The listed sponsor is Sarah Weiss, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Propranolol is the first listed.
NCT05968690 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05968690 about?
NCT05968690 is a clinical study titled "Naltrexone and Propranolol Combined With Immunotherapy". Various forms of stress can promote cancer development and growth and negatively impact the immune system's response to tumors. Beta-adrenergic and opioid receptors co-exist in many cells including immune cells and are integral components of the body's response to stress. Pre-clinical studies have d...
What is the current status of trial NCT05968690?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-09-11. Estimated completion is 2027-09-30.
What conditions does trial NCT05968690 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT05968690?
The interventions under investigation include: Propranolol (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT05968690?
This trial is sponsored by Sarah Weiss, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05968690 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
RECRUITING · Phase 1
-
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
RECRUITING · Phase 1
-
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.